Organization
Celerion Inc
1 abstract
1 poster
Poster
Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteersAbstract
Phase 1, randomized, open-label, single-dose, crossover study to evaluate the bioequivalence of four formulations of oral rivoceranib tablets in healthy subjects.Org: Celerion Inc, Tempe, AZ, Elevar Therapeutics, Salt Lake City, UT, Elevar Therapeutics, Inc.,